The Frequency and the character of bacterial infection in patients with COVID-19
https://doi.org/10.21886/2712-8156-2023-4-1-28-39
Abstract
The first human cases of new coronavirus (COVID-19), for the disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), were in Wuhan, in December 2019. By June 2022 there had been more than 500 million with confirmed cases of new coronavirus and over 5 million lives lost to the disease. During the earlier SARS-CoV-1 and MERSCoV epidemics, patients often developed bacterial coinfections and had a higher mortality rate. The aim of this work is to summarize the results of a study of the frequency and nature of bacterial infection in patients with COVID-19. Various studies was been in USA and countries of Asia and Europe show conflicting results regarding the prevalence of secondary bacterial infections in patients with COVID-19, from 1% to 50%. Bacterial co-infection is relatively infrequent in hospitalized patients with COVID-19. Risk factors of bacterial infections in patients with COVID-19 are more 60 years old, prolonged hospital length of stay, reanimation unit admission (severe disease COVID-19), chronic bacterial infection in anamnesis, immunosuppression therapy. The most common bacterial microorganisms identified in patients with infection of the lower respiratory tract, who hospital length of stay less than 48 hours are Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae. In patients, who hospital length of stay more than 48 hours the main pathogens are P. aeruginosa, Klebsiella spp., S. aureus. The data obtained indicate a low frequency of bacterial infections in patients hospitalized for COVID-19. Early infections are quite rare, more often bacterial infections are secondary and develop after 48 hours of the patient's stay in the hospital. The causative agents of early and late infections are different. Most often, an infection of the respiratory tract is noted, less often — the urinary system and bacterial infections of other localization.
About the Authors
N. A. Karoli
Saratov State Medical University n.a. V.I. Razumovsky
Russian Federation
Russian Federation
Nina A. Karoli, Dr. Sci. (Med.), professor of hospital therapy department
Saratov
A. P. Rebrov
Saratov State Medical University n.a. V.I. Razumovsky
Russian Federation
Russian Federation
Andrey P. Rebrov, Dr. Sci. (Med.), professor, head of hospital therapy department
Saratov
References
1. Taubenberger JK, Morens DM. The 1918 Influenza Pandemic and Its Legacy. Cold Spring Harb Perspect Med. 2020 Oct 1;10(10):a038695. doi: 10.1101/cshperspect.a038695.
2. Rice TW, Rubinson L, Uyeki TM et al. Critical illness from 2009 pandemic influen-za A vi-rus and bacterial coinfection in the United States. Crit Care Med. 2012 May;40(5):1487-98. doi: 10.1097/CCM.0b013e3182416f23.
3. Hoque MN, Akter S, Mishu ID et al. Microbial co-infections in COVID-19: Associat-ed mi-crobiota and underlying mechanisms of pathogenesis. Microb Pathog. 2021 Jul;156:104941. doi: 10.1016/j.micpath.2021.104941.
4. Clancy CJ, Nguyen MH. COVID-19, superinfections and antimicrobial develop-ment: what can we expect? Clin Infect Dis. 2020;ciaa524. DOI:10.1093/cid/ciaa5246,
5. Soltani S, Faramarzi S, Zandi M et al. Bacterial coinfection among coronavirus disease 2019 patient groups: an updated systematic review and meta-analysis. New Microbes New Infect. 2021 Sep;43:100910. doi: 10.1016/j.nmni.2021.100910
6. Li J, Wang J, Yang Y et al. Etiology and antimicrobial resistance of secondary bac-terial in-fections in patients hospitalized with COVID-19 in Wuhan, China: a retro-spective analysis. Anti-microb Resist Infect Control. 2020 Sep 22;9(1):153. doi: 10.1186/s13756-020-00819-1
7. Chen N, Zhou M, Dong X et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020 Feb 15;395(10223):507-513. doi: 10.1016/S0140-6736(20)30211-7.
8. Goncalves Mendes Neto A, Lo KB, Wattoo A et al. Bacterial infections and patterns of an-tibiotic use in patients with COVID-19. J Med Virol. 2021 Mar;93(3):1489-1495. doi: 10.1002/jmv.26441.
9. Russell CD, Fairfield CJ, Drake TM et al. Co-infections, secondary infections, and antimi-cro-bial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISA-RIC WHO CCP-UK study: a multicentre, prospective cohort study. Lancet Microbe. 2021 Aug;2(8):e354-e365. doi: 10.1016/S2666-5247(21)00090-2
10. Lansbury L, Lim B, Baskaran V, Lim WS. Co-infections in people with COVID-19: a sys-tematic review and meta-analysis. J Infect. 2020;81(2):266-275. doi:10.1016/j.jinf.2020.05.046
11. Miao Q, Ma Y, Ling Y et al. Evaluation of superinfection, antimicrobial usage, and airway microbiome with metagenomic sequencing in COVID-19 patients: A cohort study in Shanghai. J Microbiol Immunol Infect. 2021 Oct;54(5):808-815. doi: 10.1016/j.jmii.2021.03.015
12. Karataş M, Yaşar-Duman M, Tünger A et al. Secondary bacterial infections and an-timicrobial resistance in COVID-19: comparative evaluation of pre-pandemic and pandemic-era, a retrospective single center study. Ann Clin Microbiol Antimicrob. 2021 Aug 5;20(1):51. doi: 10.1186/s12941-021-00454-7
13. Lehmann CJ, Pho MT, Pitrak D et al. Community-acquired Coinfection in Corona-virus Dis-ease 2019: A Retrospective Observational Experience. Clin Infect Dis. 2021 Apr 26;72(8):1450-1452. doi: 10.1093/cid/ciaa902
14. Rodríguez-Baño J, Rossolini GM, Schultsz C et al. Key considerations on the po-tential im-pacts of the COVID-19 pandemic on antimicrobial resistance research and surveillance. Trans R Soc Trop Med Hyg. 2021 Oct 1;115(10):1122-1129. doi: 10.1093/trstmh/trab048.
15. Karaba SM, Jones G, Helsel T et al. Prevalence of Co-infection at the Time of Hos-pital Admission in COVID-19 Patients, A Multicenter Study. Open Forum Infect Dis. 2020 Dec 21;8(1):ofaa578. doi: 10.1093/ofid/ofaa578
16. Vijay S, Bansal N, Rao B et al. Secondary Infections in Hospitalized COVID-19 Pa-tients: Indian Experience. Infect Drug Resist. 2021 May 24;14:1893-1903. doi: 10.2147/IDR.S299774
17. Wang L, Amin AK, Khanna P et al. An observational cohort study of bacterial co-infection and implications for empirical antibiotic therapy in patients presenting with COVID-19 to hospitals in North West London. J Antimicrob Chemother. 2021 Feb 11;76(3):796-803. doi: 10.1093/jac/dkaa475
18. Lardaro T, Wang AZ, Bucca A et al. Characteristics of COVID-19 patients with bac-terial coinfection admitted to the hospital from the emergency department in a large regional healthcare system. J Med Virol. 2021 May;93(5):2883-2889. doi: 10.1002/jmv.26795
19. Coenen S, de la Court JR, Buis DTP et al. Low frequency of community-acquired bacterial co-infection in patients hospitalized for COVID-19 based on clinical, ra-diological and microbiolog-ical criteria: a retrospective cohort study. Antimicrob Re-sist Infect Control. 2021 Oct 30;10(1):155. doi: 10.1186/s13756-021-01024-4
20. Zhu X, Ge Y, Wu T et al. Co-infection with respiratory pathogens among COVID-2019 cas-es. Virus Res. 2020 Aug;285:198005. doi: 10.1016/j.virusres.2020.198005
21. Seaton RA, Gibbons CL, Cooper L et al. Survey of antibiotic and antifungal pre-scribing in patients with suspected and confirmed COVID-19 in Scottish hospitals. J Infect. 2020 Dec;81(6):952-960. doi: 10.1016/j.jinf.2020.09.024.
22. Could Efforts to Fight the Coronavirus Lead to Overuse of Antibiotics? [Internet] The Pew Charitable Trusts. 03/2021.Available from: https://www.pewtrusts.org/en/research-and-analysis/issue-briefs/2021/03/could-efforts-to-fight-the-coronavirus-lead-to-overuse-of-antibiotics
23. d'Humières C, Patrier J, Lortat-Jacob B et al. Two original observations concerning bacterial infections in COVID-19 patients hospitalized in intensive care units dur-ing the first wave of the epidemic in France. PLoS One. 2021 Apr 29;16(4):e0250728. doi: 10.1371/journal.pone.0250728;
24. Asmarawati TP, Rosyid AN, Suryantoro SD et al. The clinical impact of bacterial co-infection among moderate, severe and critically ill COVID-19 patients in the second referral hospi-tal in Surabaya. F1000Res. 2021 Feb 15;10:113. doi: 10.12688/f1000research.31645.2
25. Nori P, Cowman K, Chen V, et al. Bacterial and fungal coinfections in COVID-19 patients hospitalized during the New York City pandemic surge. Infect Control Hosp Epidemiol. 2021;42(1):84-88. doi:10.1017/ice.2020.368.
26. Kubin CJ, McConville TH, Dietz D et al. Characterization of Bacterial and Fungal Infections in Hospitalized Patients With Coronavirus Disease 2019 and Factors Associated With Health Care-Associated Infections. Open Forum Infect Dis. 2021 May 5;8(6):ofab201. doi: 10.1093/ofid/ofab201
27. Bahceci I, Yildiz IE, Duran OF et al. Secondary Bacterial Infection Rates Among Patients With COVID-19. Cureus. 2022 Feb 18;14(2):e22363. doi: 10.7759/cureus.22363
28. Shah R, Shah J, Gohil J et al. Secondary Infections in Patients with COVID-19 Pneumonia Treated with Tocilizumab Compared to Those Not Treated with Tocili-zumab: A Retrospective Study at a Tertiary Hospital in Kenya. Int J Gen Med. 2022 Mar 3;15:2415-2425. doi: 10.2147/IJGM.S356547
29. Valik JK, Hedberg P, Holmberg F et al. Impact of the COVID-19 pandemic on the inci-dence and mortality of hospital-onset bloodstream infection: a cohort study. BMJ Qual Saf. 2022 May;31(5):379-382. doi: 10.1136/bmjqs-2021-014243
30. Sturdy A, Basarab M, Cotter M et al. Severe COVID-19 and healthcare-associated infec-tions on the ICU: time to remember the basics? J Hosp Infect. agosto de 2020; 105(4):593–5. https://doi.org/10.1016/j.jhin.2020.06.027
31. Youngs J, Wyncoll D, Hopkins P et al. Improving antibiotic stewardship in COVID-19: Bac-terial co-infection is less common than with influenza. J Infect. 2020 Sep;81(3):e55-e57. doi: 10.1016/j.jinf.2020.06.056.
32. Dhesi Z., Enne V.I., Brealey D. et al. Organisms causing secondary pneumonia in COVID-19 patients in 5 UK ICUs as detected with the FilmArray test https://www.medrxiv.org/content/10.1101/2020.06.22.20131573v1.full.pdf;
33. Van Laethem J, Wuyts S, Van Laere S et al. Antibiotic prescriptions in the context of sus-pected bacterial respiratory tract superinfections in the COVID-19 era: a ret-rospective quantitative analysis of antibiotic consumption and identification of an-tibiotic prescription drivers. Intern Emerg Med. 2021 Jun 29:1–11. doi: 10.1007/s11739-021-02790-0
34. Buehler PK, Zinkernagel AS, Hofmaenner DA et al. Bacterial pulmonary superin-fections are associated with longer duration of ventilation in critically ill COVID-19 patients. Cell Rep Med. 2021 Apr 20;2(4):100229. doi: 10.1016/j.xcrm.2021.100229
35. Vaughn VM, Gandhi TN, Petty LA et al. Empiric Antibacterial Therapy and Com-munity-onset Bacterial Coinfection in Patients Hospitalized With Coronavirus Dis-ease 2019 (COVID-19): A Multi-hospital Cohort Study. Clin Infect Dis. 2021;72(10):e533-e541. doi:10.1093/cid/ciaa1239
36. Suranadi IW, Sucandra IMAK, Fatmawati NND, Wisnawa ADF. A Retrospective Analysis of the Bacterial Infections, Antibiotic Use, and Mortality Predictors of COVID-19 Patients. Int J Gen Med. 2022 Apr 1; 15: 3591-3603. doi: 10.2147/IJGM.S351180
37. Rajni E, Garg VK, Bacchani D et al. Prevalence of Bloodstream Infections and their Etiolo-gy in COVID-19 Patients Admitted in a Tertiary Care Hospital in Jaipur. Indian J Crit Care Med 2021;25(4):369–373. DOI: 10.5005/jp-journals-10071-23781
38. Grasselli G, Scaravilli V, Mangioni D et al. Hospital-Acquired Infections in Critically Ill Pa-tients With COVID-19. Chest. 2021 Aug;160(2):454-465. doi: 10.1016/j.chest.2021.04.002
39. Khurana S, Singh P, Sharad N, et al. Profile of co-infections & secondary infec-tions in COVID-19 patients at a dedicated COVID-19 facility of a tertiary care Indian hospital: Implication on antimicrobial resistance. Indian J Med Microbiol. 2021 Apr;39(2):147-153. doi: 10.1016/j.ijmmb.2020.10.014
40. Karami Z, Knoop BT., Dofferhoff AS. et al. Few bacterial co-infections but frequent empiric antibiotic use in the early phase of hospitalized patients with COVID-19: results from a multicentre retrospective cohort study in The Netherlands, Infectious Diseases, 2021; 53:2, 102-110, DOI:10.1080/23744235.2020.1839672
41. Hughes S, Troise O, Donaldson H et al. Bacterial and fungal coinfection among hospitalized patients with COVID-19: a retrospective cohort study in a UK second-ary-care setting. Clin Micro-biol Infect. 2020 Oct;26(10):1395-1399. doi: 10.1016/j.cmi.2020.06.025.
42. Garcia-Vidal C, Sanjuan G, Moreno-Garcı ´a E. et al. Incidence of co-infections and superin-fections in hospitalized patients with COVID-19: a retrospective cohort study. Clin Microbiol In-fect. 2020; https://doi.org/10.1016/j.cmi.2020.07.041
43. Stevenson DR, Sahemey M, Cevallos Morales J et al. Improving Antimicrobial Stewardship in Critically-Ill Patients with COVID-19. Clin Infect Dis. 2021 Jun 1;72(11):e926. doi: 10.1093/cid/ciaa1559;
44. Lingscheid T, Lippert LJ, Hillus D et al. Characterization of antimicrobial use and co-infections among hospitalized patients with COVID-19: a prospective observa-tional cohort study. Infection. 2022 Apr 14:1–12. doi: 10.1007/s15010-022-01796-w
45. Baskaran V, Lawrence H, Lansbury LE et al. Co-infection in critically ill patients with COVID-19: an observational cohort study from England. J Med Microbiol. 2021 Apr;70(4):001350. doi: 10.1099/jmm.0.001350
46. Chong WH, Saha BK, Ananthakrishnan Ramani, Chopra A. State-of-the-art review of sec-ondary pulmonary infections in patients with COVID-19 pneumonia. Infec-tion. 2021 Aug;49(4):591-605. doi: 10.1007/s15010-021-01602-z.
47. Bhatraju PK, Ghassemieh BJ, Nichols M et al. Covid-19 in Critically Ill Patients in the Seat-tle Region - Case Series. N Engl J Med. 2020 May 21;382(21):2012-2022. doi: 10.1056/NEJMoa2004500.
48. Zhou F, Yu T, Du R et al. Clinical course and risk factors for mortality of adult inpa-tients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3.
49. Magnasco L, Mikulska M, Giacobbe DR et al. Spread of Carbapenem-Resistant Gram-Negatives and Candida auris during the COVID-19 Pandemic in Critically Ill Patients: One Step Back in Antimicrobial Stewardship? Microorganisms. 2021 Jan 3;9(1):95. doi: 10.3390/microorganisms9010095
50. Chertow DS, Memoli MJ. Bacterial coinfection in influenza: a grand rounds review. JAMA. 2013 Jan 16;309(3):275-82. doi: 10.1001/jama.2012.194139.
51. Cataño-Correa JC, Cardona-Arias JA, Porras Mancilla JP, García MT. Bacterial su-perinfection in adults with COVID-19 hospitalized in two clinics in Medellín-Colombia, 2020. PLoS One. 2021 Jul 13;16(7):e0254671. doi: 10.1371/journal.pone.0254671
52. Adebisi YA, Alaran AJ, Okereke M et al. COVID-19 and Antimicrobial Resistance: A Re-view. Infect Dis (Auckl). 2021 Jul 31;14:11786337211033870. doi: 10.1177/11786337211033870
53. Gu S, Chen Y, Wu Z et al. Alterations of the Gut Microbiota in Patients With Coro-navirus Disease 2019 or H1N1 Influenza. Clin Infect Dis. 2020 Dec 17;71(10):2669-2678. doi: 10.1093/cid/ciaa709.
54. Musuuza JS, Watson L, Parmasad V et al. Prevalence and outcomes of co-infection and su-perinfection with SARS-CoV-2 and other pathogens: A systematic review and meta-analysis. PLoS One. 2021 May 6;16(5):e0251170. doi: 10.1371/journal.pone.0251170
55. He S, Liu W, Jiang M et al. Clinical characteristics of COVID-19 patients with clini-cally diagnosed bacterial co-infection: A multi-center study. PLoS One. 2021 Apr 5;16(4):e0249668. doi: 10.1371/journal.pone.0249668.
56. Bhatt PJ, Shiau S, Brunetti L et al. Risk Factors and Outcomes of Hospitalized Pa-tients With Severe Coronavirus Disease 2019 (COVID-19) and Secondary Blood-stream Infections: A Multicenter Case-Control Study. Clin Infect Dis. 2021 Jun 15;72(12):e995-e1003. doi: 10.1093/cid/ciaa1748
57. Clancy CJ, Schwartz IS, Kula B, Nguyen MH. Bacterial Superinfections Among Persons With Coronavirus Disease 2019: A Comprehensive Review of Data From Postmortem Studies. Open Forum Infect Dis. 2021 Feb 4;8(3):ofab065. doi: 10.1093/ofid/ofab065
58. Westblade LF, Simon MS, Satlin MJ. Bacterial Coinfections in Coronavirus Dis-ease 2019. Trends Microbiol. 2021 Oct;29(10):930-941. doi: 10.1016/j.tim.2021.03.018.
59. Ruiz-Bastián M, Falces-Romero I, Ramos-Ramos JC et al. Bacterial co-infections in COVID-19 pneumonia in a tertiary care hospital: Surfing the first wave. Diagn Microbiol Infect Dis. 2021;101(3):115477. doi:10.1016/j.diagmicrobio.2021.115477
60. Ansari S, Hays JP, Kemp A et al. The potential impact of the COVID-19 pandemic on glob-al antimicrobial and biocide resistance: an AMR Insights global perspective. JAC Antimicrob Resist. 2021 Apr 8;3(2):dlab038. doi: 10.1093/jacamr/dlab038
61. Fu Y, Yang Q, Xu M et al. Secondary Bacterial Infections in Critical Ill Patients With Coro-navirus Disease 2019. Open Forum Infect Dis. 2020 Jun 5;7(6):ofaa220. doi: 10.1093/ofid/ofaa220.
62. Rothe K, Feihl S, Schneider J et al. Rates of bacterial co-infections and antimicro-bial use in COVID-19 patients: a retrospective cohort study in light of antibiotic stewardship. Eur J Clin Mi-crobiol Infect Dis. 2021;40(4):859-869. doi:10.1007/s10096-020-04063-8
63. May M, Chang M, Dietz D et al. Limited Utility of Procalcitonin in Identifying Com-munity-Associated Bacterial Infections in Patients Presenting with Coronavirus Disease 2019. An-timicrob Agents Chemother. 2021 Mar 18;65(4):e02167-20. doi: 10.1128/AAC.02167-20.
64. Chen S, Zhu Q, Xiao Y et al. Clinical and etiological analysis of co-infections and secondary infections in COVID-19 patients: An observational study. Clin Respir J. 2021 Jul;15(7):815-825. doi: 10.1111/crj.13369
65. Nasir N, Rehman F, Omair SF. Risk factors for bacterial infections in patients with moderate to severe COVID-19: A case-control study. J Med Virol. 2021 Jul;93(7):4564-4569. doi: 10.1002/jmv.27000;
66. Cultrera R, Barozzi A, Libanore M et al. Co-Infections in Critically Ill Patients with or with-out COVID-19: A Comparison of Clinical Microbial Culture Findings. Int J Envi-ron Res Public Health. 2021 Apr 20;18(8):4358. doi: 10.3390/ijerph18084358;
67. Abdollahi A, Aliramezani A, Salehi M, et al. Co-infection of ST2IP carbapenem-resistant Acinetobacter baumannii with SARS-CoV-2 in the patients admitted to a Tehran tertiary referral hospital. BMC Infect Dis. 2021 Sep 8;21(1):927. doi: 10.1186/s12879-021-06642-2
68. Pavlovich N.V., Tsimbalistova M.V., Aronova N.V., Anisimova A.S., Vodopyanov S.O., Vodopyanov A.S., Gudueva E.N., Sagakyants M.M., Kovalev E.V., Noskov A.K. Community-acquired pneumonia of bacterial etiology and the spectrum of sensitivity of pathogens to antibiotics in corona-positive and corona-negative patients in Rostov-on-Don. Antibiot i khimioter. 2021; 66: 1–2: 26–32. doi: 10.24411/0235-2990-2021-66-1–2-26-32 (in Russian).
69. Jesaulenko N.B., Tkachenko O.V. Changes in the sensitivity of the bacterial flora in patients with COVID-19. The results of your own research. Klinicheskaja laboratornaja diagnostika. 2021; S4: 80 (in Russian). https://www.elibrary.ru/item.asp?id=45607901
70. Klein EY, Monteforte B, Gupta A et al. The frequency of influenza and bacterial coinfec-tion: a systematic review and meta-analysis. Influenza Other Respir Viruses. 2016 Sep;10(5):394-403. doi: 10.1111/irv.12398.
71. Amin-Chowdhury Z, Aiano F, Mensah A. et al. Impact of the Coronavirus Disease 2019 (COVID-19) Pandemic on Invasive Pneumococcal Disease and Risk of Pneumococcal Coinfection With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Prospective National Co-hort Study, England. Clin Infect Dis. 2021 Mar 1;72(5):e65-e75. doi: 10.1093/cid/ciaa1728.
72. Hu R, Han C, Pei S, et al. Procalcitonin levels in COVID-19 patients. Int J Antimi-crob Agents. 2020 Aug;56(2):106051. doi: 10.1016/j.ijantimicag.2020.106051.
73. Langford BJ, So M, Raybardhan S et al. Bacterial co-infection and secondary in-fection in patients with COVID-19: a living rapid review and meta-analysis. Clin Mi-crobiol Infect. 2020 Dec;26(12):1622-1629. doi: 10.1016/j.cmi.2020.07.016.
74. Profilaktika, diagnostika I lechenie novoy koronavirusnoy infektsii (COVID-19). Vremennye metodicheskie rekomendatsii. Versiya 15 (22.02.2022) (in Russian). https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/059/392/original/%D0%92%D0%9C%D0%A0_COVID-19_V15.pdf
75. Sieswerda E, de Boer MGJ, Bonten MMJ et al. Recommendations for antibacterial therapy in adults with COVID-19 - an evidence based guideline. Clin Microbiol In-fect. 2021 Jan;27(1):61-66. doi: 0.1016/j.cmi.2020.09.041
76. Lucien MAB, Canarie MF, Kilgore PE et al. Antibiotics and antimicrobial resistance in the COVID-19 era: Perspective from resource-limited settings. Int J Infect Dis. 2021 Mar;104:250-254. doi: 10.1016/j.ijid.2020.12.087.
77. Pawar A, Desai RJ, Solomon DH et al. Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study. Ann Rheum Dis. 2019 Apr;78(4):456-464. doi: 10.1136/annrheumdis-2018-214367.
78. Guaraldi G, Meschiari M, Cozzi-Lepri A et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study. Lancet Rheumatol. 2020 Aug;2(8):e474-e484. doi: 10.1016/S2665-9913(20)30173-9.
79. Somers EC, Eschenauer GA, Troost JP et al. Tocilizumab for treatment of mechan-ically ven-tilated patients with COVID-19 [manuscript published online ahead of print 11 July 2020]. Clin In-fect Dis 2020. doi:10.1093/cid/ciaa954
80. Tleyjeh IM, Kashour Z, Riaz M et al. Efficacy and safety of Tocilizumab in COVID-19 pa-tients: a living systematic review and meta-analysis, first update. Clin Micro-biol Infect. 2021;27(8):1076–1082. doi:10.1016/j.cmi.2021.04.019
81. Group TWREAfC-TRW. Association between administration of IL-6 antagonists and mor-tality among patients hospitalized for COVID-19 A meta-analysis. JAMA. 2021;326(6):499–518. doi:10.1001/jama.2021.11330
82. Salama C, Han J, Yau L et al. Tocilizumab in patients hospitalized with Covid-19 pneumo-nia. N Engl J Med. 2021;384(1):20–30. doi:10.1056/ NEJMoa2030340
83. Rosas IO, Brau N, Waters M, et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. N Engl J Med. 2021;384(16):1503–1516. doi:10.1056/NEJMoa2028700
Review
For citations:
Karoli N.A., Rebrov A.P. The Frequency and the character of bacterial infection in patients with COVID-19. South Russian Journal of Therapeutic Practice. 2023;4(1):28-39. (In Russ.) https://doi.org/10.21886/2712-8156-2023-4-1-28-39
Views:
1916
Email this article 